Godley ISD closes because of illness abundance
Jan. 29—Godley ISD officials on Tuesday announced that the district is closing until Monday because of an abundance of absences due to illness — flu, COVID and other viruses.
"Just today, almost 650 students were absent with all campuses reporting low attendance rates in the 70-80% range; several more students went home sick from school throughout the day," according to a note sent to parents.
kAmx? 255:E:@? E@ E96 DEF56?E 23D6?46D[ @G6C e_ DE277 2?5 E62496CD H6C6 2=D@ 23D6?E]k^Am
kAm"(6 5@ ?@E >236C @7 DE277 2?5 E62496C 23D6?46D AC6G6?ED FD 7C@> D276=J 2?5 67764E:G6=J 4@G6C:?8 4=2DD6D 2?5 @E96C 5FE:6D[" 5:DEC:4E @77:4:2=D D2:5]k^Am
kAm%F6D52J ?:89E'D 24E:G:E:6D AC@466565 2D ?@C>2=] u@C E96 C6>2:?56C @7 E96 H666D 2?5 D@>6 @E96C DA64:7:4 6IEC24FCC:4F=2C 24E:G:E:6D H:== AC@4665 :7 4@2496D 2?5 DA@?D@CD 56E6C>:?6 E92E E96:C 8C@FAD 42? A2CE:4:A2E6] r2>AFD6D H:== @E96CH:D6 36 4=@D65 E@ J@FE9 2E9=6E:4 24E:G:E:6D]k^Am
kAm"%96 5:DEC:4E 6?4@FC286D 72>:=:6D E@ FD6 E9:D E:>6 7@C DEF56?ED 2?5 DE277 E@ C64@G6C 2?5 86E H6== D@ E92E H6 42? C6EFC? >F49 962=E9:6C ?6IE H666 E@ 4@?E:?F6 566A 4=62?:?8 2?5 D2?:E:K2E:@? @7 D49@@= 3FD6D 2?5 3F:=5:?8D[ :?4=F5:?8 4=2DDC@@>D[ 4276E6C:2D[ 8J>D[ =@4D 2?5 @E96C A2CED @7 42>AFD6D]k^Am
kAm~G6C 2 ac\9@FC DA2? E96 D2>6 52J[ E96 r@@r9:=5C6?'D t>6C86?4J s6A2CE>6?E :? u@CE (@CE9 D2H 4=@D6 E@ f__ A2E:6?ED]k^Am
kAm"(9:49 :D ;FDE 2? 2DEC@?@>:42= ?F>36C[" r@@r9:=5C6?'D 2EE6?5:?8 A9JD:4:2? sC] $E6A92?:6 u6=E@? E@=5 rq$ }6HD] "tG6CJ J62C[ H6 @3G:@FD=J D66 E96 7=F] %9:D J62C[ x H:== D2J[ E92E H6'C6 D66:?8 2? 23F?52?46 @7 :E[ 2D 72C 2D E96 ?F>36CD]"k^Am
kAmx? E96 =2E6DE C6A@CE:?8 A6C:@5 @7 y2?] 'a\'g[ %6I2D C6A@CE65 2 bc A6C46?E A@D:E:G:EJ C2E6 7@C E96 7=F DE2E6H:56[ 244@C5:?8 E@ 52E2 7C@> %6I2D s6A2CE>6?E @7 $E2E6 w62=E9 $6CG:46D C6=62D65 uC:52J] t# G:D:ED :?4C62D65 bb]cb A6C46?E 7@C E92E H662D H6==]k^Am
kAm~? E96 ?2E:@?2= =6G6=[ E96 r6?E6CD 7@C s:D62D6 r@?EC@= C6A@CE65 2 ad A6C46?E :?4C62D6 7@C A@D:E:G6 7=F 42D6D 5FC:?8 E96 D2>6 E:>6 A6C:@5]k^Am
kAm!C6G6?E:@? 2?5 EC62E>6?Ek^Am
kAm%96C6 2C6 24E:@?D J@F 42? E2 E96D6 G:CFD6D[ 2?5 :7 E96J 2C6 DAC625:?8 :? J@FC 4@>>F?:EJ]k^Am
kAm%96 rsr @776CD C64@>>6?52E:@?D E@ 3@E9 96=A 2?5 EC62E E96 7=F] tG6CJ @?6 e >@?E9D 2?5 @=56C D9@F=5 86E 2? 2??F2= 7=F G244:?6[ :562==J 3J E96 6?5 @7 ~4E@36C 3FE A6@A=6 D9@F=5 4@?E:?F6 E@ 86E G244:?2E65 2D =@?8 2D 7=F G:CFD6D A@D6 2 E9C62E E@ E96:C 4@>>F?:EJ]k^Am
kAm%96 rsr 2=D@ C64@>>6?5Dik^Am
kAm—pG@:5 4=@D6 4@?E24E H:E9 A6@A=6 H9@ 2C6 D:4:E 4@?E24E H:E9 @E96CD 2D >F49 2D A@DD:3=6 E@ :?764E:?8 E96>] u@C 7=F[ rsr C64@>>6?5D E92E A6@A=6 DE2J 9@>6[ 7@C 2E =62DE ac 9@FCD[ F?E:= 3@E9 2C6 ECF6i J@FC DJ>AE@>D 2C6 86EE:?8 36EE6C @G6C2==[ 2?5 J@F 92G6 ?@E 925 76G6C W2?5 2C6 ?@E FD:?8 76G6C\C65F4:?8 >65:42E:@?X]k^Am
kAm—r@G6C J@FC ?@D6 2?5 >@FE9 H:E9 2 E:DDF6 H96? J@F 4@F89 @C D?66K6] %9C@H E96 E:DDF6 :? E96 EC2D9 27E6C J@F FD6 :E]k^Am
kAm—(62C:?8 2 >2D:D 2? 255:E:@?2= AC6G6?E:@? DEC2E68J E92E J@F 42? 49@@D6 E@ 7FCE96C AC@E64E J@FCD6=7 2?5 @E96CD] (96? H@C? 3J 2 A6CD@? H:E9 2? :?764E:@?[ >2D 3C62E9:?8 :? :?764E:@FD A2CE:4=6D 7C@> A6@A=6 2C@F?5 E96>]k^Am
kAm—(2D9 J@FC 92?5D @7E6? H:E9 D@2A 2?5 H2E6C] x7 D@2A 2?5 H2E6C 2C6 ?@E 2G2:=23=6[ FD6 2? 2=4@9@=\32D65 92?5 CF3]k^Am
kAm—pG@:5 E@F49:?8 J@FC 6J6D[ ?@D6[ 2?5 >@FE9] v6C>D DAC625 E9:D H2J]k^Am
kAm—*@F 42? :>AC@G6 2:C BF2=:EJ 3J 3C:?8:?8 :? 7C6D9 @FED:56 2:C[ AFC:7J:?8 :?5@@C 2:C[ @C 82E96C:?8 @FE5@@CD]k^Am
kAm—%2]k^Am
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
3 hours ago
What to know about COVID variant NB.1.8.1 causing 'razor blade throat'
A newer COVID-19 variant may be causing a severe sore throat in some people who contract the infection. The variant, known as NB.1.8.1, has been nicknamed by some as "razor blade throat" due to the painful symptom. Data from the open global genome sequencing database GISAID shows the new variant has been detected in several states, including New York, Illinois, Texas and California. Public health experts told ABC News there is no cause for serious concern yet because the virus does not appear to be more severe than previous variants and there are steps that can be taken to protect yourself. What is NB 1.8.1? NB.1.8.1 derives from the recombinant variant XVD.1.5.1, which is a descendant of the omicron variant. The first sample of NB.1.8.1 was collected on Jan. 22, according to the World Health Organization (WHO). It was first detected in China and other parts of Asia before spreading to Europe. It was designated as a "variant under monitoring" by the WHO, meaning it may require prioritized attention and monitoring but is not as serious as a "variant of interest" or a "variant of concern." As of the week ending June 7, NB.1.8.1 is the second most dominant variant in the U.S., accounting for an estimated 37% of cases, according to the Centers for Disease Control and Prevention (CDC). The virus appears to be more transmissible because there appear to be changes to the spike protein, which is what the virus uses to attach to and infect cells, said Dr. Peter Chin-Hong, a professor of medicine and infectious disease specialist at the University of California, San Francisco. It also seems to attach more easily to ACE2 receptors, which are proteins found on the surface of cells and how the virus that causes COVID enters cells, he told ABC News. NB.1.8.1 doesn't yet appear to be causing increases in cases or in hospitalizations with rates remaining "stable" so far, according to Chin-Hong. The variant has also been called "Nimbus," which appears to have been coined on X by T. Ryan Gregory, a Canadian professor of evolutionary biology. "Nimbus is a catchy, quick name, and it also includes an 'N' and a 'B' from the lineage, which is NB.1.8.1. So it's easier for people to be able to say these monikers for COVID, rather than remember the actual lineage," said Dr. Alok Potel, a pediatrician at Stanford Children's Health and an ABC News contributor. "But I think it's important also because it keeps people paying attention to new COVID variants that can be different in terms of infectivity and in terms of spread," he added. What are the symptoms? Experts said they are not sure if the painful sore throat is just a symptom that people are talking about or a distinctive symptom of this variant. It's also unclear if the "razor blade throat" is more common in those who are more up to date on vaccination compared to those who are not up to date. "I think it's certainly amongst the spectrum of symptoms that you can get, and we know that sore throat is reported by about 70% of patients now with COVID, so it's not unusual, and like with everything in medicine, there's always a spectrum," Chin-Hong said. There is currently no evidence that NB.1.8.1. causes more severe disease or is more likely to cause hospitalization, according to Dr. William Schaffner, a professor of preventive medicine at Vanderbilt University Medical Center in Nashville, "But of course, there are people in high-risk groups that are still at risk of being hospitalized should they become infected," he told ABC News. There are no other symptoms outlined that are specific to NB.1.8.1 by the CDC. Symptoms listed by the health agency still include sore throat, cough, fever, chills, shortness of breath, difficulty breathing, congestion, runny nose, loss of taste or smell, fatigue, muscle aches, body aches, headache, nausea, vomiting or diarrhea. How to protect yourself The experts recommend that high-risk Americans receive a vaccine twice a year as recommended by the CDC. The CDC also currently recommends most adults aged 18 and older receive an updated 2024-2025 vaccine and that parents of children between ages 6 months to 17 years discuss the benefits of vaccination with a health care provider. COVID-19 also tends to spike in the late summer and early fall, so people should consider opening windows to increase ventilation, wearing a mask in certain situations and avoiding crowded areas, Schaffner said. "Time to stream a movie, as I like to say, rather than going to the movies," he added. Patel said it's important to practice good hygiene such as proper hand-washing and covering your mouth when coughing or sneezing. He also recommended that people test if they are symptomatic and said over-the-counter rapid at-home tests work. "Getting infected with COVID and other infectious diseases is not necessarily life or death, but it can still be very debilitating." Patel said. "It can cause people to miss work, to spread the virus, to get people who are higher risk sick and there's still an untold amount of people who have long COVID." He added, "So, we don't want to look at COVID as just another common cold, because there's still so much we're learning about it, and there's still so many possibilities with this virus continuing to mutate, if we let it."
Epoch Times
5 hours ago
- Epoch Times
COVID ‘Razor Throat' Variant Now Found in 15 US States: Here's What We Know
The COVID-19 variant that has driven a rise in cases in mainland China is now detected in more than a dozen U.S. states, according to data released by a private tracking firm. Earlier in the week, Chinese doctors
Newsweek
9 hours ago
- Newsweek
HIV: Supercharged Vaccine Could Protect Well With Just One Dose
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. A supercharged HIV vaccine could offer strong protection with just one injection, a study in mice has indicated. Developed by researchers from the Massachusetts Institute of Technology (MIT) and the Scripps Research Center, the vaccine includes two "adjuvants"—materials that help stimulate the immune system response. In the experiments, the dual-adjuvant vaccine was found to produce a wider diversity of antibodies to protect against an HIV protein than with either single adjuvant or none at all. This was because the vaccine accumulated in the mice's lymph nodes and remained there for a month—giving their immune systems more time to build up antibodies against HIV. "What's potentially powerful about this approach is that you can achieve long-term exposures based on a combination of adjuvants that are already reasonably well-understood, so it doesn't require a different technology," said paper author and MIT chemical engineer professor J. Christopher Love in a statement. And, the researchers said, the same approach could be used to create one-shot-only vaccines against other diseases, including COVID-19 and influenza. A man receives a vaccination. A man receives a vaccination. Rani Nurlaela Desandi/iStock / Getty Images Plus Most vaccines administered today are accompanied by adjuvants to help make them more effective. One often used with protein-based vaccines—such as given against hepatitis A and B—is "alum," short for "aluminum hydroxide." Alum activates the body's innate immune response, helping it to form a stronger memory of the vaccine antigen in case of a real infection. The new HIV vaccine combines alum with a nanoparticle known as SMNP, which itself combines the FDA-approved, naturally derived adjacent saponin with an inflammation-promoting molecule. In their study, the researchers found that the SMNP–alum combination helped the HIV protein in their vaccine both penetrate the protective layer of cells surrounding the lymph nodes without being broken down, as well as stay intact in the nodes for up to 28 days. The lymph nodes are where protective "B cells" are exposed to antigens—the substances that the body uses to recognize a given infection—and learn to produce the antibodies to fight back. Vaccine antigens (pink) concentrate in B cell follicles (cyan) Vaccine antigens (pink) concentrate in B cell follicles (cyan) MIT "As a result, the B cells that are cycling in the lymph nodes are constantly being exposed to the antigen over that [up to 28 day] time period—and they get the chance to refine their solution to the antigen," Love explained. He added: "When you think about the immune system sampling all of the possible solutions, the more chances we give it to identify an effective solution, the better." When the researchers analyzed the RNA of the B cells from the vaccinated mice, they found that those who had received both adjuvants had produced a more diverse array of B Cells and antibodies than the other rodents. In fact, those who received the dual-adjuvant vaccine produced more than twice as many unique B cells than those mice who received a single-adjuvant vaccine. This, the team explained, increases the odds that the mice's immune systems will be able to produce antibodies against a variety of strains of HIV in the case of a future injection. And the benefits of the dual-adjuvant tactic is not just limited to fighting HIV. "This approach is compatible with many protein-based vaccines, so it offers the opportunity to engineer new formulations for these types of vaccines across a wide range of different diseases, such as influenza, SARS-CoV-2, or other pandemic outbreaks," said Love. Do you have a tip on a health story that Newsweek should be covering? Do you have a question about HIV? Let us know via health@ Reference Rodrigues, K. A., Zhang, Y. J., Lam, J., Aung, A., Morgan, D. M., Romanov, A., Maiorino, L., Yousefpour, P., Gibson, G., Ozorowski, G., Gregory, J. R., Amlashi, P., Van, R., Buckley, M., Ward, A. B., Schief, W. R., Love, J. C., & Irvine, D. J. (2025). Vaccines combining slow release and follicle targeting of antigens increase germinal center B cell diversity and clonal expansion. Science Translational Medicine, 17(803).
